|
所属 |
附属病院 脳神経外科 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2023年04月-継続中
秋田大学 附属病院 脳神経外科 講師
-
2017年07月-2023年03月
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 機能展開医学系 助教
職務経歴（学外） 【 表示 ／ 非表示 】
-
2023年04月-継続中
秋田大学大学院 脳神経外科 講師
-
2017年07月-継続中
秋田大学大学院 脳神経外科 助教
-
2015年11月-2017年06月
ハイデルベルク大学神経 神経病理学研究室 客員研究員
研究経歴 【 表示 ／ 非表示 】
-
IDH-wildtype gliomaにおける悪性化機構の解明
科学研究費補助金
研究期間：
2019年04月-継続中研究態様：個人研究
-
IDHミュータント神経膠腫の病理分類と 悪性度に関する研究
国際共同研究
研究期間：
2015年11月-2017年10月研究態様：国際共同研究
-
テモゾロミド耐性悪性グリオーマに対するインターフェロンβ，ベバシズマブ併用テモゾロミド療法におけるアミノ酸トレーサを用いた効果判定の重要性
科学研究費補助金
研究期間：
2011年04月-2015年03月研究態様：国内共同研究
研究等業績 【 表示 ／ 非表示 】
-
Wakasa R.
Brain Research ( Brain Research ) 1850 2025年03月 [査読有り]
研究論文（学術雑誌）
-
Kanamori M.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 30 ( 1 ) 51 - 61 2025年01月 [査読有り]
研究論文（学術雑誌）
Abstract
Background
To improve the outcome in newly diagnosed glioblastoma patients with maximal resection, we aimed to evaluate the efficacy and safety of implantation of carmustine wafers (CWs), radiation concomitant with temozolomide and bevacizumab, and maintenance chemotherapy with six cycles of temozolomide and bevacizumab.
Method
This prospective phase II study enrolled glioblastoma patients considered candidates for complete resection (> 90%) of a contrast-enhanced lesion. The CWs were intraoperatively implanted into the resection cavity after achieving maximal resection. Patients without a measurable contrast-enhanced lesion on magnetic resonance imaging within 48 h after resection received concomitant radiotherapy and chemotherapy with temozolomide and bevacizumab, followed by maintenance treatment with up to six cycles of temozolomide and bevacizumab. The primary endpoint was the 2-year overall survival rate in glioblastoma patients with protocol treatment.
Results
From October 2015 to April 2018, we obtained consent for the first registration from 70 patients across 17 institutions in Japan, and 49 patients were treated according to the protocol. We evaluated the safety in 49 patients who were part of the second registration and the efficacy in 45 glioblastoma patients treated according to the protocol. The profile of hematological and most of the non-hematological adverse effects was similar to that in previous studies, but stroke occurred in 12% of cases (6/49 patients). The estimated 2-year overall survival rate was 51.3%.
Conclusion
Implantation of CWs, followed by concomitant radiation, temozolomide, and bevacizumab, and six cycles of temozolomide and bevacizumab may offer some benefit to survival in Japanese glioblastoma patients with maximal resection.
Trial ID
jRCTs021180007. -
Identifying the appropriate measurement environment for laser speckle flowmetry of cerebral blood flow in rats
Ryosei Wakasa, Takahiro Ono, Naomoto Senbokuya, Mikiko Kuwayama, Hiroaki Shimizu
Brain Research ( Elsevier BV ) 149443 - 149443 2025年01月 [査読有り]
研究論文（学術雑誌）
-
Shape of the first mitotic spindles impacts multinucleation in human embryos
Ono Y.
Nature Communications ( Nature Communications ) 15 ( 1 ) 2024年12月 [査読有り]
研究論文（学術雑誌）
Abstract
During human embryonic development, early cleavage-stage embryos are more susceptible to errors. Studies have shown that many problems occur during the first mitosis, such as direct cleavage, chromosome segregation errors, and multinucleation. However, the mechanisms whereby these errors occur during the first mitosis in human embryos remain unknown. To clarify this aspect, in the present study, we image discarded living human two-pronuclear stage zygotes using fluorescent labeling and confocal microscopy without microinjection of DNA or mRNA and investigate the association between spindle shape and nuclear abnormality during the first mitosis. We observe that the first mitotic spindles vary, and low-aspect-ratio-shaped spindles tend to lead to the formation of multiple nuclei at the 2-cell stage. Moreover, we observe defocusing poles in many of the first mitotic spindles, which are strongly associated with multinucleation. Additionally, we show that differences in the positions of the centrosomes cause spindle abnormality in the first mitosis. Furthermore, many multinuclei are modified to form mononuclei after the second mitosis because the occurrence of pole defocusing is firmly reduced. Our study will contribute markedly to research on the occurrence of mitotic errors during the early cleavage of human embryos. -
Takahiro Ono, Hayato Suzuki, Hiroshi Nanjo, Hiroaki Shimizu
Journal of neuro-oncology ( Journal of Neuro-Oncology ) 168 ( 3 ) 393 - 404 2024年05月 [査読有り]
研究論文（学術雑誌）
PURPOSE: It remains unclear whether combining carmustine wafer (CW) implantation with the standard treatment for adult-type diffuse gliomas is safe and has a prognostic impact. This study aimed to investigate the prognostic value and safety of CW implantation. METHODS: Adult patients with IDH-wild-type and -mutant gliomas, grades 3-4 treated with surgical resection, radiotherapy, and temozolomide chemotherapy between 2013 and 2023 were surveyed. CWs were implanted except in cases of intraoperative wide ventricle opening or marked preoperative brain swelling. For survival analyses, a case-matched dataset based on propensity score matching (PSM), including multiple factors (patient background, diagnosis, and extent of resection) was generated. Progression-free survival (PFS), overall survival (OS), and frequency of complications of CW implantation (brain edema, infection, and cerebrospinal fluid leakage) were compared between the CW and non-use groups. RESULTS: In total, 127 patients (75 in the CW use group and 52 in the non-use group) were enrolled. Regardless of stratification, no significant differences in PFS and OS were observed between the CW use and non-use groups. The frequency of postoperative brain edema was significantly higher in the CW use group than in the non-use group. An adjusted dataset containing 41 patients in the CW use and nonuse groups was generated. Even after PSM, CW implantation had no prognostic effect. CONCLUSIONS: CW implantation with standard treatment demonstrated little beneficial effect for the present strategy of CW use.
-
内科医が知っておくべき脳出血の急性期治療
小野隆裕，清水宏明
Medicina ( 医学書院 ) 2016年02月
総説・解説（商業誌） 国内共著
-
自動迅速免疫染色装置を活かす簡易型自動薄切装置の開発(Development of automatic slice device that utilizes automatic rapid immunostaining device)
南條 博, 廣嶋 優子, 佐藤 寛恭, 吉野 雅彦, 今井 一博, 寺田 かおり, 小野 隆裕, 中村 竜太, 赤上 陽一, 南谷 佳弘
日本病理学会会誌 ( (一社)日本病理学会 ) 113 ( 1 ) 332 - 332 2024年02月
-
桑山 実喜子, 小野 隆裕, 富樫 俊太郎, 髙橋 和孝, 清水 宏明
神経外傷 ( 一般社団法人 日本脳神経外傷学会 ) 46 ( 1 ) 12 - 19 2023年06月 [査読有り]
Although the surgical indication of acute subdural hematoma (ASDH) is described in guidelines, outcomes of initial conservative management have not been investigated in detail. The purpose of the present study was to clarify frequency and causes of neurological aggravation during initial conservative management for ASDH.
Patients with ASDH treated at the Akita University Hospital between April 2014 and September 2022 were reviewed retrospectively. Patients who received initial conservative management because of non–severe neurological deficits were divided into two groups; with or without further neurological aggravation. Risk factors, reasons of the aggravation, treatment after the aggravation and clinical outcomes were analyzed.
In a total of 73 patients with ASDH, 58 (79.5%) patients were initially managed conservatively. Among 42 non–severe cases, 30 (71.4%) patients had no further neurological aggravation. Twelve (28.6%) patients with neurological aggravation (between day 1 – 11) had significantly thicker initial ASDHs and lower Glasgow Coma Scales at discharge than those without aggravation. The causes of the aggravation included hematoma enlargement and seizure in 2 cases each, systemic complications in 1, and others in 7 cases. In the last 7 cases, hyperintensity lesions in the cerebral cortex adjacent to the hematoma on arterial spin labelling (ASL) images were observed in 6 cases and abnormal electroencephalography (EEG) findings (spike–and–waves or slow waves) in 3 cases. In four of these 7 cases, hematoma removal was performed resulting in improving their clinical symptoms.
In conclusion, in patients with ASDH who were initially managed conservatively due to non–severe neurological deficits, further aggravation was observed in 12 (28.6%). Six (50.0%) of these showed ASL and/or EEG findings that may not contradict non–convulsive seizures. To clarify the causes of neurological aggravation during initial conservative management more precisely, further investigation employing continuous EEG will be expected. -
12年の経過で悪性転化した星細胞腫における,病理・分子生物学的変化 症例報告
高木 いさん, 小野 隆裕, 高橋 和孝, 清水 宏明
秋田医学 ( 秋田医学会 ) 49 ( 3-4 ) 131 - 138 2023年03月 [査読有り]
-
自動迅速免疫染色装置(Auto R-IHC)の開発と活用
南條 博, 廣嶋 優子, 今井 一博, 寺田 かおり, 小野 隆裕, 中村 竜太, 大久保 義真, 赤上 陽一, 南谷 佳弘
日本病理学会会誌 ( (一社)日本病理学会 ) 112 ( 1 ) 268 - 268 2023年03月
-
間接血行再建術後に対側脳血流の改善がみられた成人もやもや病の1例
富樫 俊太郎, 木村 早希, 阿部 真道, 高橋 佑介, 小野 隆裕, 高橋 和孝, 清水 宏明
脳循環代謝 ( (一社)日本脳循環代謝学会 ) 34 ( 1 ) 140 - 140 2022年10月
◆原著論文【 表示 ／ 非表示 】
◆総説・解説【 表示 ／ 非表示 】
◆その他【 表示 ／ 非表示 】
学術関係受賞 【 表示 ／ 非表示 】
-
第33回山下太郎学術研究奨励賞
2022年06月01日 一般財団法人山下太郎顕彰育英会 病理学および分子生物学的解析を統合した、悪性髄内腫瘍の診断の最適化
受賞者： 小野隆裕
科研費（文科省・学振）獲得実績 【 表示 ／ 非表示 】
-
テクスチャ解析と分子解析に基づく、gliomaの病理診断法の刷新
基盤研究(C)
研究期間: 2024年04月 - 2029年03月 代表者: 小野 隆裕
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月 代表者: 小野 隆裕
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月 代表者: 小野 隆裕
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月 代表者: 小野 隆裕
-
IDH-wildtype gliomaにおける悪性化機構の解明
若手研究
研究期間: 2019年04月 - 2023年03月 代表者: 小野 隆裕